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Angiopoietin-like 4 (ANGPTL4) is a secreted protein which belongs to the angiopoietin
family and is involved in angiogenesis and metabolism regulation. We previously reported the
induction of angptl4 by hypoxia in endothelial cells and in human ischemic tissues from
peripheral artery disease. We here observed in a mouse model of hindlimb ischemia that the
mRNA upregulation in the vessels correlates with the accumulation of the full-length protein
in ischemic tissues. We then investigated its functions in endothelial cells. In response to
hypoxia, endogenous ANGPTL4 accumulates in the subendothelial extracellular matrix
(ECM). Whereas the secreted protein undergoes proteolysis leading to truncated fragments
present in the medium, only full-length ANGPTL4 interacts with the ECM. Competition and
direct binding assays indicate that the strong interaction of ANGPTL4 with the ECM is
heparin/heparan sulfate proteoglycans dependent. The balance between matrix-associated and
soluble forms of ANGPTL4 points out the role of the ECM in the regulation of its
bioavailability. The angiogenic function of the ECM-bound full-length protein was
investigated using either the form associated with the conditioned ECM from ANGPTL4-
transfected HEK293 cells, or the purified immobilized protein. We show that matrix-
associated as well as immobilized ANGPTL4 limit the formation of actin stress fibers and
focal contacts in the adhering endothelial cells and inhibits their adhesion. Immobilized
ANGPTL4 also decreases motility of endothelial cells and inhibits the sprouting and tube
formation. Altogether, these findings show that hypoxic endothelial cells accumulate
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Cardiovascular disorders such as coronary and peripheral artery diseases lead to a
deficient blood supply to tissues and a decrease in oxygen partial pressure, i.e. hypoxia.
Because of their location at the interface of circulating blood and peripheral tissues,
endothelial cells are exposed to hypoxia. A critical adaptation to hypoxia is angiogenesis
which consists in the formation of new blood vessels extending from the pre-existing
vasculature.1 This phenomenon occurs through the activation of the endothelial cells by a
multistep process including changes of cell-extracellular matrix (ECM) interactions. In
ischemic cardiovascular pathologies, reactive angiogenesis is a profitable event. Therefore
unraveling the interplay of multiple molecular signals and events which occur in hypoxia and
lead to functional new blood vessels is a challenging issue.
We previously identified angiopoietin-like 4 (angptl4) as a hypoxia-induced gene in
vitro in human microvascular endothelial cell line (HMEC-1) and in vivo in the vessels of
ischemic tissues from peripheral artery disease.2 Human ANGPTL4 is a secreted glycoprotein
which belongs to the angiopoietin family.3 It is composed of 406 amino acids and contains an
amino-terminal signal sequence, a coiled-coil domain and a carboxy-terminal fibrinogen-like
domain. ANGPTL4 oligomerizes and undergoes proteolysis mediated by a cell-associated
protease.4
Angiopoietins are major regulators of the balance between destabilization and
stabilization of the vasculature occuring during angiogenesis. The angiopoietin-1 tightens
vessels by promoting interactions between cells of the vascular wall whereas the
angiopoietin-2 loosens these interactions and stimulates the growth of immature vessels.5,6
Angiopoietin-like proteins also play a role in the modulation of angiogenesis, as shown for
ANGPTL17,8, ANGPTL28,9, ANGPTL310 and ANGPTL4.2,3,11,12 ANGPTL4, previously known
as hepatic fibrinogen/angiopoietin-related protein (HFARP)3, peroxisome proliferator-
activated receptor- (PPAR-) angiopoietin-related gene (PGAR)13 or fasting induced adipose
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factor (FIAF)14 is also involved in lipid and glucose metabolism.15-17
In the pathological context of ischemic diseases, ANGPTL4 could modulate
angiogenesis by modifying the microenvironment in response to hypoxia. A crucial
determinant of cell microenvironment is the ECM, whose regulated composition plays a
pivotal role in neovessel formation, stability and maturation.18 The ECM is mainly composed
of fibrous proteins, like collagen or fibronectin, and interstitial glycosaminoglycans
covalently bound to core proteins to form proteoglycans such as heparan sulfate
proteoglycans (HSPGs). The interaction of growth factors, including angiopoietin-1 and
VEGF, with the ECM in the vicinity of the production site regulates their bioavailability.19,20
In the present study using in vivo and in vitro models, we investigated the expression
of ANGPTL4, its interaction with the ECM and its bioactivity on endothelial cells. We report
that full-length ANGPTL4 accumulates in the mouse ischemic hindlimb after vascular
ligature and in the ECM of hypoxic endothelial cells through heparin/HSPGs. ECM-bound
ANGPTL4 reduces endothelial cell adhesion, prevents the organization of focal adhesions
and actin stress fibers, decreases cell migration and sprouting. Therefore, ANGPTL4, through
its autocrine effect on endothelial cells, participates in the modulation of angiogenesis in a
hypoxic microenvironment.
Materials and Methods
Cell culture, expression and purification of recombinant ANGPTL4, immunofluorescence,
statistical analysis, antibodies and reagents are described in the online data supplement.
Extraction of ECM-associated proteins
ECM was prepared, according to a protocol adapted from Owensby 21, by incubating cells in 5
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Mouse model of hindlimb ischemia
Unilateral hindlimb ischemia was induced by ligation and excision of the femoral artery in
C57BL/6 mice, as previously described.22 Mice were sacrificed at day 2 or 6 (three mice per
group). Tissues from both hindlimbs were either fixed in 4% paraformaldehyde (PFA) and
paraffin embedded, either snap-frozen and stored at -80°C until used. Probe labelling by in
vitro transcription and in situ hybridization were performed as previously described on
paraffin sections, with an antisense mouse ANGPTL4 probe.23 Total proteins were extracted
from frozen tissues for Western-blot analysis.
Adhesion assay
Conditioned ECM were prepared from Human Embryonic Kidney 293 cells (HEK293) grown
to confluence for 48 hours and lifted by 5 mmol/L EDTA. Alternatively, plates were coated
overnight at 4°C with increasing concentrations of purified ANGPTL4. Plates were saturated
with 1% BSA. Trypsinized endothelial cells were plated in complete medium. Adherent cells
were fixed one hour after plating in 4% PFA, stained with 0.1% crystal violet and quantified
by measuring the absorbance at 570 nm.
Migration assay
Transwell filters (8 µm pores) were coated on the lower side with fibronectin (10 µg/mL) ±
ANGPTL4 at various concentrations. Human Umbilical Vein Endothelial Cells (HUVEC)
were seeded on the upper side of the membrane in ECBM2 with 0,2% FCS for 2 hours. Cells
from the upper side were mechanically removed and cells from lower side were fixed. Nuclei
were stained with 4’-6 Diamidino-2-phenylindole (DAPI) and counted.
Time-lapse videomicroscopy
HUVEC were detached by 10 mmol/L EDTA and seeded in complete medium on wells
coated with fibronectin and/or purified ANGPTL4. After 40 min, cells were recorded at a 5
min lapse interval for 5 hours on inverted Leica microscope IRBE equipped with 10x PH 0.40
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objective lenses, enclosed in a Life Imaging Services environmental incubator. Images were
acquired using a Coolsnap HQ Roper Scientific camera. Motion-analysis was performed with
the MetaMorph software.
Tube formation assay
Culture wells were coated on ice with Matrigel (Collaborative Biochemical Products,
Bedford, MA) alone or mixed with ANGPTL4 (1 or 5 µg/mL). After 30 min at 37°C, HMEC-
1 were seeded on top and further incubated for 24 hours in the presence of 0.5% FCS. The
number of tubes was counted from four pictures acquired per condition with a 4x objective.
Sprouting assay
Spheroids of 500 HUVEC were generated as previously described24 and embedded in
collagen gels containing ANGPTL4 (1 µg/mL) or not. Endothelial sprouting was stimulated
with 20 ng/mL VEGF for 24 hours. Sprouting intensity was quantitated by determining the
cumulative sprout length per spheroid using an Olympus IX50 inverted microscope and the
Cell P software (Soft Imaging System, Germany). The mean of the cumulative sprout length
of 10 randomly selected spheroids was analyzed as an individual data point.
Results
ANGPTL4 accumulates in ischemic hindlimb
Having previously shown that ANGPTL4 mRNA is upregulated in the vessel wall of
human ischemic limbs2, we addressed the issue in a mouse model of hindlimb ischemia. In
situ hybridization at day 6 after ligature showed an upregulation of ANGPTL4 mRNA in the
interstitial capillaries of the ischemic leg compared to the controlateral one (Figure 1A) but
not in the muscular fibers. Full-length mouse ANGPTL4 protein was also overexpressed in
the ischemic limb (Figure 1B).
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Hypoxia-induced endogenous ANGPTL4 accumulates in the extracellular matrix
of endothelial cells
Since the vessels are a site of expression of ANGPTL4 in ischemic tissues, the
hypoxic regulation of the protein was further analyzed in primary cultures of HUVEC. The
expression of full-length ANGPTL4 (55 kDa) was markedly induced in conditioned medium
(CM) from HUVEC grown in hypoxia (1% O2) for 48 hours, as compared to cells grown in
normoxia (21% O2) (Figure 2A, top panel). A high level of full-length ANGPTL4 was
associated to the ECM and was greatly increased by hypoxia (Figure 2A, bottom panel). The
binding properties of ANGPTL4 to the ECM have been compared to those of the
matricellular proteins Cyr61/CCN1, which strongly binds the HSPGs, and Nov/CCN3, which
displays a weak interaction with the matrix.25 As shown in Figure 2A, Nov was detected in the
CM and was absent from the ECM extract whereas Cyr61 was both detected in the CM and
the ECM. Immunofluorescence analysis of unpermeabilized HUVEC in hypoxic condition
showed that the distribution of ANGPTL4 in the ECM was diffuse without visible fibrillar
organization, in a pattern similar to Cyr61 (Figure 2B). Nov was not detected in the ECM.
ANGPTL4 was also accumulated in the ECM of hypoxic endothelial cells from
microvascular origin i.e. primary culture of Human Dermal Microvascular Cells (HDMEC)
and HMEC-1 (Figure 2C). ANGPTL4 accumulation in the matrix is regulated by the level
and duration of hypoxia. Whereas 10% O2 for two days failed to up-regulate matrix
associated-ANGPTL4 in the HUVEC, a 5% O2 exposure induced a detectable increase of the
ANGPTL4 level (Figure 2D). Thus the amount of ECM-bound ANGPTL4 depends on the
level of oxygen. Besides, ANGPTL4 accumulation is rapidly reversible. Reoxygenation of the
HUVEC for 24 hours reverted the ECM-bound protein amount to its basal level (Figure 2E).
Altogether, ANGPTL4 accumulation occurs in the endothelial ECM in mild to severe hypoxic
conditions via a dynamic process.
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Interaction of full-length ANGPTL4 with ECM regulates its bioavailability
ANGPTL4 undergoes oligomerization and proteolytic processing in the CM of cell
culture or in plasma.4,26 To determine which form interacts with the ECM, recombinant
ANGPTL4 tagged with either myc-his or flag C-terminal epitope was expressed in
dihydrofolate reductase-deficient Chinese Hamster Ovary (CHO-DHFR) cells, HEK293 cells
or HUVEC. Full-length ANGPTL4 was detected in the CM and the ECM of the three cell
types (Figure 3). In non reducing conditions, two bands of higher molecular weight
corresponding to oligomeric forms were detected indicating that ANGPTL4 monomers and
oligomers interact with the ECM (Figure 3A).
To evaluate the ratio of matrix-bound versus soluble ANGPTL4, CHO-DHFR-
ANGPTL4-myc cells were seeded in serum-free medium and grown for 24 hours. CM and
ECM were prepared from an equal cell number. Most of the full-length ANGPTL4 was
accumulated in the ECM (Figure 3B, left panel). A C-terminal proteolytic fragment was
identified in the CM. This 35 kDa-fragment was absent from the ECM fraction. Accordingly,
HUVEC expressing ANGPTL4-myc displayed two bands of 55 and 35 kDa in the CM,
indicating that endothelial cells are also able to process the soluble ANGPTL4. This
phenomenon could not be revealed for the endogenous protein since the anti-ANGPTL4
antibody does not allow the recognition of the 35 kDa form. In agreement with the detection
of endogenous ANGPTL4 in the ECM, only full-length 55 kDa recombinant ANGPTL4
interacted with the ECM from HUVEC (Figure 3B, right panel).
To further investigate the distribution of ANGPTL4 in the ECM and the medium,
varying ratios of HEK293 and HEK293-ANGPTL4-flag cells were seeded in serum-free
medium for 24 hours. Using a low ratio of ANGPTL4 expressing cells (Figure 3C, first lane
in both panels), the full-length ANGPTL4 was detected in the ECM, whereas the C-terminal
fragment alone was detected in the CM. With increasing proportions of HEK293-ANGPTL4,
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ECM-bound ANGPTL4 still consisted of the full-length protein while increasing amounts of
both full-length and processed ANGPTL4 were detected in the CM. These experiments
suggest that full-length ANGPTL4 is preferentially accumulated in the ECM until it reaches a
saturation level.
ANGPTL4 strongly binds to the endothelial ECM and interacts with heparin and
heparan sulfate proteoglycans
The strength of the interaction of ANGPTL4 with the ECM was then characterized.
Recombinant ANGPTL4 was first allowed to interact with the ECM of normoxic HUVEC
containing few endogenous ANGPTL4. ECM-associated ANGPTL4 was analyzed after
treatment with increasing concentrations of NaCl (Figure 4A and B). Full-length ANGPTL4
displayed a strong association with the ECM as 0.8 mol/L NaCl was required to release more
than 50% of the bound protein from the ECM. Furthermore, ANGPTL4 was still detected in
presence of 1.2 mol/L NaCl.
ANGPTL4 could accumulate in the ECM through interaction with HSPGs, as
previously reported for Cyr61.25 Increasing amounts of heparin added to the culture medium
of HEK293-ANGPTL4 cells led to a dose-dependent displacement of the full-length protein
from the ECM to the medium, suggesting a competition between soluble heparin and matrix
HSPGs for recombinant ANGPTL4 binding (Figure 4C). Moreover in the presence of heparin
(50 µg/mL), endogenous ANGPTL4 was shifted from the ECM of hypoxic HUVEC into the
CM, as well as Cyr61 (Figure 4D). Similar results have been obtained with microvascular
endothelial cells (data not shown). Full-length ANGPTL4 was applied on heparin-sepharose
affinity column to further investigate a potential direct interaction. ANGPTL4 efficiently
bound to heparin since it was eluted at 0.7 mol/L NaCl (Figure 4E). This strong affinity of
ANGPTL4 for heparin was in a range similar to that previously reported for Cyr61.27
Moreover, in a solid phase binding assay, purified full-length ANGPTL4 interacted with
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immobilized heparin as well as immobilized HSPGs, whereas it weakly interacted with BSA
(Figure 4F). Altogether, our results demonstrate that both recombinant and endogenous full-
length ANGPTL4 strongly interact with the ECM in a heparin/HSPGs dependent manner.
Matrix-bound ANGPTL4 inhibits endothelial cell adhesion to the ECM
The functional role of the ECM-bound full-length ANGPTL4 was then investigated.
Conditioned ECM from HEK293 or HEK293-ANGPTL4-flag cells were used to quantify the
adhesion of endothelial cells one hour after plating. As compared to control ECM, HUVEC
adhesion was decreased by 32.7 ± 16.7% on ANGPTL4-containing ECM (Figure 5A). To
check the direct involvement of ANGPTL4 in the anti-adhesive effect, endothelial adhesion
was analyzed on increasing concentrations of purified immobilized protein (Figure 5B).
HUVEC adhesion was reduced in a dose-dependent way, reaching 39.5 ± 9.7% of decrease on
5 µg/mL ANGPTL4. Adhesion of Human Umbilical Artery Endothelial Cells (HUAEC) and
HMEC-1 on ANGPTL4 were also decreased by 52.4 ± 5.7% and 28.4 ± 8.2% respectively,
when compared to control adhesion (Figure 5C).
Matrix-bound ANGPTL4 prevents the formation of actin stress fibers and the
organization of focal contacts of adhering endothelial cells
Cell adhesion on ECM affects cytoskeletal dynamics. The organization of the actin
cytoskeleton of endothelial cells was investigated during the adhesion process on ANGPTL4.
HUVEC were plated on conditioned ECM either from HEK293 or HEK293-ANGPTL4-flag
cells (Figure 6A). Two hours after plating on the control ECM, cells displayed a well ordered
array of transversal actin stress fibers extending to focal adhesions evidenced by vinculin.
This organized cytoskeleton was similar to that from HUVEC adhering on fibronectin. In
contrast, HUVEC adhering on ECM from HEK293-ANGPTL4 cells were almost devoid of
actin stress fibers and focal adhesions. HUVEC displayed a similar disorganized cytoskeleton
on purified immobilized ANGPTL4 compared to control coating. On wild-type ECM, 57.3 ±
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6.7% HUVEC displayed stress fibers versus 29.7 ± 3.9% on ECM containing ANGPTL4. On
control buffer, 67.4 ± 3.7% cells displayed an organized cytoskeleton versus 38.7± 5.8% on
purified ANGPTL4 (Figure 6B, top panel). The alteration of actin organization and focal
adhesion distribution induced by ANGPTL4 was dose-dependent (Figure 6B, bottom panel).
A time course of the effect of ECM-associated ANGPTL4 was performed during the
adhesion process (Figure 6C). The dynamic reorganization of actin fibers and focal adhesion
progressed over the next 4 hours after adhesion on control ECM. In contrary, stress fibers
failed to form up to 4 hours after plating on ANGPTL4-containing ECM.
Immobilized ANGPTL4 inhibits endothelial cell migration
Endothelial cell migration is an essential step of the angiogenic process. A migration
assay was performed in a Transwell system where the lower side of the membrane was coated
with fibronectin in the absence or presence of ANGPTL4 (Figure 7A). HUVEC showed a
decreased locomotion towards fibronectin when immobilized ANGPTL4 was added.
Furthermore, this effect was dose-dependent with a maximal reduction of 47 % of the number
of cells that had migrated (Figure 7A, right panel).
Cell migration was further analyzed by time-lapse videomicroscopy. The motility
tracking of individual HUVEC plated on various coatings was monitored. Six representative
paths from 28 to 48 analyzed cells are shown in Figure 7B, left panel. Immobilized
ANGPTL4 decreased HUVEC migration speed when compared to plastic or fibronectin alone
(control : 23.08 ± 5.16 µm/hour; ANGPTL4 : 14.34 ± 5.22 µm/hour; fibronectin : 40.62 ±
10.18 µm/hour), as quantified in Figure 7B, right panel. Furthermore, ANGPTL4
immobilized in presence of fibronectin was able to counteract the fibronectin-induced high
motility (ANGPTL4 + fibronectin : 28.20 ± 7.37 µm/hour). Movies are shown in
supplemental Figure I.
Matrix-bound ANGPTL4 inhibits tube formation and sprouting
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The ability of microvascular endothelial cells to form tubes was assessed in Matrigel
containing increasing concentrations of full-length ANGPTL4. Tubes formation of HMEC-1
was reduced on ANGPTL4 and Matrigel when compared to Matrigel alone (Figure 8A and
B). To further characterize the role of ANGPTL4 in the sprouting process, we used a 3D
spheroid model.24 HUVEC spheroids were stimulated to sprout in a collagen gel in the
absence or presence of immobilized ANGPTL4. Figure 8C shows representative spheroids for
each condition and the sprouting was quantified on panel D. Whereas ANGPTL4 embedded
in the collagen gel has no statistically significant effect in basal conditions, it decreased the
sprouting of VEGF-stimulated HUVEC.
Discussion
Previous in vivo studies reported a strong upregulation of angptl4 mRNA in human
samples from critical leg ischemia2 and an inhibition of angiogenesis and vascular leakiness.11
In this study, we observed an accumulation of the protein in a mouse model of hindlimb
ischemia. Altogether, these data suggest a pathophysiological role of ANGPTL4 in altering
efficient neovascularization in ischemic tissues. Thus deciphering the cellular mechanisms of
the angiogenic responses to ANGPTL4 is an important issue.
We here demonstrate that ANGPTL4, a member of the angiopoietin family, strongly
interacts with the ECM through HSPGs and that matrix-bound ANGPTL4 inhibits endothelial
cell adhesion, cytoskeleton organization, migration and sprouting. Angiopoietin-1 also
interacts with the ECM whereas angiopoietin-2 is more diffusible.19 These interactions
provide different local concentrations, involve other proteins as co-receptors and are thought
to account in part for the differences in the biological effect of the angiopoietins. In addition
to the transcriptional regulation by hypoxia2,28, PPARs agonists and nutritional factors13,14,26,
we here propose a new regulatory mechanism of the bioavailability of ANGPTL4 through
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ECM binding. This interaction with the ECM participates in concentrating the full-length
protein near its production site. Consistently we found an increase in full-length ANGPTL4 in
the mouse ischemic muscle while the interstitial vessels appear as a major expression site.
Altogether these findings suggest that the ECM from the vascular wall might constitute a
dynamic reservoir of ANGPTL4. Its up-regulation by hypoxia could be involved in
microenvironment modifications occuring in ischemic events. This hypothesis can not be
fully tested in vivo, given the paucity of tools to detect endogenous ANGPTL4.
We show here a direct interaction of ANGPTL4 with heparin. However a higher salt
concentration was required to release ANGPTL4 from subendothelial ECM than from the
heparin-sepharose. This suggests that other ECM components are likely involved in the
interaction between ANGPTL4 and the matrix. A putative heparin-binding motif has been
found in ANGPTL3, the closest related known member of the family29, whereas no consensus
sequence exists in ANGPTL4. However many heparin-binding proteins do not display a
consensus sequence, suggesting rather the implication of a structural heparin-binding motif
which remains to be identified for ANGPTL4.
ANGPTL4 is proteolyzed in vitro and in vivo and circulates in the peripheral blood
mainly as truncated fragments4,26, suggesting the relative instability of the full-length soluble
form. Interestingly, we show here that full-length ANGPTL4 preferentially interacts with the
ECM. This binding may protect ANGPTL4 from proteolysis and regulate its processing.
Differences in the ratio of the full-length and truncated forms reported in human liver and
adipose tissue26 could partly result from a variable ANGPTL4 binding capacity to the ECM in
these organs.
Once incorporated in the ECM, full-length ANGPTL4 could be part of the guidance
cues provided by the matrix to the endothelial cells and involved in vascular morphogenesis
and angiogenesis.18 Cell adhesion on the ECM is a dynamic process involving attachment,
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spreading and formation of focal adhesions and stress fibers, which generate a strong
adhesive state. A state of intermediate adhesion, characterized by a fairly spread shape of the
cells with disruption of focal adhesions and disassembly of actin stress fibers, is thought to
represent the physiological «de-adhesion» process, allowing tissue remodeling.30 Some
ECM-associated proteins, the matricellular proteins, which include thrombospondin-1 (TSP-
1), Secreted Protein Acidic and Rich in Cystein (SPARC) and the CCN family of proteins
(Cyr61, Connective Tissue Growth Factor, Nov) regulate cell-matrix interactions.31 In the
present study, the anti-adhesive activity induced by matrix-associated ANGPTL4 is similar to
that observed for TSP-1 or SPARC. The cytoskeleton disorganization could explain the
defective migration of endothelial cells on an attractive substratum as fibronectin.
The pathway leading to the inhibition of endothelial cell adhesion, migration and
cytoskeleton disruption is likely to involve the integrin family, which are primary ECM
receptors. ANGPTL4, similarly to the angiopoietins32, or ANGPTL310 could directly bind an
integrin, or inhibit cell-ECM interaction through a downstream impairement of integrin
function. ANGPTL4 receptor has not been characterized yet and these hypotheses need
further investigation.
In summary, ANGPTL4 is a hypoxia-induced angiogenic modulator, whose
bioavailability is regulated by a strong interaction with the ECM and which acts as a
chemorepellent and disorganizes the actin cytoskeleton of endothelial cells. Thus, ECM-
bound ANGPTL4 may be involved through an autocrine pathway in the highly regulated
vascular morphogenesis occuring in response to hypoxia.
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Figure 1. Expression of ANGPTL4 in mice ischemic hindlimbs. Ischemic and controlateral
tibialis anterialis muscles were harvested at day 2 or 6 post ligation of the left femoral artery.
A, At day 6, non ischemic muscle shows normal histology with Hematoxylin and Eosin
staining (a) and no detectable signal in vessels nor muscle fibers after in situ hybridization
with the FIAF antisense probe (c). Ischemic muscle shows fiber necrosis, interstitial oedema
and inflammatory infiltrate (b). Signal is detected in small vessels (arrows) in ischemic areas
with the FIAF antisense probe (d). Bar = 100 µm. B, Western-blot analysis of muscle protein
extracts (100 µg/lane) with anti-mouse ANGPTL4 (top panel) or anti-tubulin (bottom panel).
Transfected mouse ANGPTL4 was used as a positive control.
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Figure 2. Interaction of ANGPTL4 with the ECM from endothelial cells in hypoxic
conditions. A, B and C, endothelial cells were grown in 21% or 1% O2 for two days. A,
Western-blot analysis of the CM or ECM from HUVEC was performed using anti-
ANGPTL4, anti-Cyr61 and anti-Nov antibodies. B, Immunofluorescence was performed on
unpermeabilized HUVEC, with anti-ANGPTL4 (left panel), anti-Cyr61 (medium panel) and
anti-Nov (right panel) antibodies. Bar = 40 µm. C, Western-blot analysis of ECM from
microvascular endothelial cells. D and E, Western-blot analysis with anti-ANGPTL4 of ECM
from HUVEC. D, Cells were grown in the indicated O2 concentrations for two days. E, Cells
were grown under various conditions : 21% O2 (continuous line) for four days (a); 1% O2
(hatched line) for four (b) or five (d) or six (f) days; 1% O2 for four days followed by 21% O2
for one (c) or two days (e). Cells were cultured in presence of 25 µg/mL heparin for the CM
analysis and in absence of heparin for the ECM analysis. Results are representative of three
independent experiments.
Figure 3. Accumulation of full-length ANGPTL4 in the ECM. A, CM or ECM from CHO-
DHFR-ANGPTL4-myc cells was analyzed by Western-blot using anti-myc antibody on 7.5%
SDS-PAGE in reducing (+DTT) or non-reducing (-DTT) conditions. B, CM or ECM from
CHO-DHFR-ANGPTL4-myc cells or transfected HUVEC was analyzed by Western-blot
using anti-myc antibody. C, Increasing ratios of HEK293-ANGPTL4-flag versus HEK293
cells were plated in the indicated proportions and grown until confluence. CM (left panel) and
ECM (right panel) were analyzed by Western-blot using anti-flag antibody. Results are
representative of three independent experiments.
Figure 4. Full-length ANGPTL4 strongly interacts with the ECM through heparin and
HSPGs. A and B, CM from HEK293-ANGPTL4-flag cells (Input) was incubated on ECM
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from normoxic HUVEC. ECM was then treated by NaCl at the indicated concentrations for 2
hours. ANGPTL4 in the post-incubation ECM was analyzed by Western-blot (A) using anti-
flag antibody and quantified (B) using the Quantity One software (Bio-Rad Laboratories). C
and D, HEK293-ANGPTL4 cells (C) or hypoxic HUVEC (D) were grown in the presence of
increasing amounts of heparin as indicated. ECM and CM from the same plate were analyzed
by Western-blot using anti-flag (C) or anti-ANGPTL4 and anti-Cyr61 antibodies (D). E, The
elution profile of ANGPTL4-flag from a heparin-sepharose affinity column with a NaCl
gradient was analyzed by Western-blot using anti-flag antibody. F, Direct binding of purified
ANGPTL4-myc-his (1 µg/mL) to immobilized HSPGs (60 µg/mL), heparin (50 µg/mL) or
BSA (10 mg/mL) was measured in triplicate in a solid phase binding assay. Results are
representative of three independent experiments. Quantification indicate mean ± SD of three
independent experiments.
Figure 5. ANGPTL4 inhibits adhesion of endothelial cells. A, HUVEC were plated on
conditioned ECM from wild-type HEK293 cells (WT ECM) or from HEK293-ANGPTL4
cells (ANGPTL4 ECM). Basal adhesion (at 100%) was set on control WT ECM. B and C,
Human endothelial cells (B: HUVEC, C: HUAEC or HMEC-1) were plated on purified
immobilized ANGPTL4. Basal adhesion (at 100%) was set on control buffer. Results are
mean ± SD of three independent experiments for HUVEC and of triplicates of one
representative experiment for HUAEC and HMEC-1.
Figure 6. ANGPTL4 inhibits the organization of actin cytoskeleton in HUVEC. A,
Morphology and actin cytoskeleton were analyzed after plating cells either on fibronectin (5
µg/mL), ECM from wild-type HEK293 cells (WT ECM), ECM from HEK293-ANGPTL4
cells (ANGPTL4 ECM), control buffer or immobilized ANGPTL4 (1 µg/mL). Two hours
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after adhesion, cells were processed for immunofluorescence with Rhodamin-Phalloidin (red),
anti-vinculin (green), TO-PRO®-3 (blue). Bar = 20 µm. B, Actin cytoskeleton organization
was quantified after two hours adhesion on the indicated coatings (top panel) or on
immobilized ANGPTL4 (bottom panel). Data are mean ± SD of three independent
experiments, *:p=0.05, **:p=0.02. C, Time course of actin cytoskeleton organization during
the adhesion process. Bar = 20 µm. Representative pictures were taken from one out of three
independent experiments.
Figure 7. ANGPTL4 reduces endothelial cell migration. A, HUVEC migrated through the
Transwell membrane. Left panel, field (objective X5) of the control (fibronectin alone) and
ANGPTL4 (10 µg/mL) bottom side of Transwell using DAPI nuclear staining. Right panel,
quantification of cells which migrated towards fibronectin in the absence or presence of
ANGPTL4. Results are mean ± SD of three independent experiments, *p=0.05. B, Time-lapse
videomicroscopy. Left panel, migration paths of individual HUVEC seeded on plastic
(control), fibronectin (5 µg/mL) ± ANGPTL4 (5 µg/mL). Each point indicates the position
(XY coordinates) of the cell at 5-min intervals. Position of 62 consecutive intervals are
shown. Right panel, quantification of the cell velocity. Results are mean ± SD of 28 to 48
independent cells in a representative experiment out of three independent experiments.
***p=0.001.
Figure 8. ANGPTL4 decreases tube formation and sprouting of endothelial cells. A and
B, HMEC-1 were seeded on Matrigel containing various concentrations of ANGPTL4. Tube
formation was assessed after 24 hours. A, Tubes formed on Matrigel alone (top) or on
Matrigel containing 5 µg/mL ANGPTL4 (bottom). B, Quantification of tube number. Results
are mean ± SD of three independent experiments. C and D, The sprouting assay was
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performed on HUVEC spheroids embedded in collagen ± ANGPTL4. C, Representative
spheroids without (top) or with (bottom) ANGPTL4. D, Quantification of sprouting. Results
are mean ± SD of three independent experiments, *p=0.05.
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